Trinity Biotech (TRIB) Long-Term Deferred Tax (2009 - 2025)

Trinity Biotech's Long-Term Deferred Tax history runs 17 years deep, the most recent figure standing at $3.9 million for Q4 2025.

• In Q4 2025, Long-Term Deferred Tax fell 96.2% year-over-year to $3.9 million; the TTM figure through Dec 2025 stood at $3.9 million (down 96.2% YoY), while the FY2025 annual figure was $3.9 million, down 96.2% from the prior year.
• Long-Term Deferred Tax came in at $3.9 million for Q4 2025 at Trinity Biotech, up from $3.5 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $103.3 million in Q4 2024 to a low of $694000.0 in Q3 2024.
• A 5-year average of $8.8 million and a median of $3.8 million in 2021 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax soared 5129.87% in 2024 and tumbled 96.2% in 2025, its largest moves.
• Trinity Biotech's Long-Term Deferred Tax stood at $4.1 million in 2021, then rose by 2.85% to $4.2 million in 2022, then tumbled by 53.18% to $2.0 million in 2023, then jumped by 5129.87% to $103.3 million in 2024, then sank by 96.2% to $3.9 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $3.9 million, $3.5 million, and $103.3 million for Q4 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison